M&A / Deals Supernus and Indivior merge to create scaled, CNS-focused entity Pharmaceutical TechnologyThrough this merger, Supernus and Indivior will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs).NeuroscienceRead full story pharminent August 4, 2026 (Last updated: August 8, 2026) Pharmaceutical Technology Through this merger, Supernus and Indivior will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs). Neuroscience Read full story Post navigation Previous: Pathos AI signs two cancer deals with Alphamab and AZNext: Pfizer Axes Ex-Metsera Obesity Asset and GIPR Prospect in Quarterly Pipeline Clearout Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026